Pure Biologics partners with Twist Bioscience to accelerate Pure Biologics’ antibody-based immuno-oncology drug discovery process. Utilizing Twist Bioscience Hyperimmune scFv Library, Pure Biologics identified new antibodies binding to the targets from their pipeline that were further validated in cell-binding assays. The library allowed generation of antibodies meeting the initial desired characteristics of a future drug candidate. Obtained antibodies (i) are cross-reactive to human and cyno homologues of the target; (ii) are highly specific and do not bind to similar proteins from the family of the target; or (iii) recognize a protein complex. These results emphasize the usefulness of the Hyperimmune scFv Library in the conditions of applied drug development projects, as well as highlight the Pure Biologics' chosen targets' capability for antibody raising from phage libraries, as well as robust and efficient discovery strategies applied.